Epidemiology, pathogenesis of primary hyperparathyroidism: Current data [0.03%]
原发性甲状旁腺功能亢进症的流行病学、发病机制：现有数据
Claudio Marcocci,Federica Saponaro
Claudio Marcocci
Pascal Houillier
Pascal Houillier
Fritz-Line Vélayoudom-Céphise,Jean-Louis Wémeau
Fritz-Line Vélayoudom-Céphise
Primary hyperparathyroidism (PHPT) and vitamin D (VD) deficiency are frequent conditions due to the widespread application of assays for calcium and VD. PHPT presentation is dominated by diversity in its expression and the current predomina...
Jean-Louis Wémeau
Jean-Louis Wémeau
Christine Do Cao,Sébastien Aubert,Clémentine Trinel et al.
Christine Do Cao et al.
Parathyroid carcinoma is a little-known cancer, difficult to diagnose. We focus this short review on the current diagnostic criteria, the classification and the evaluation tools for this cancer based on latest publications. ...
Treatment of heterotopic ossifications secondary to pseudohypoparathyroid [0.03%]
次发假性副甲状腺功能减退的异位骨化治疗
Vincent Guigonis,Claire Bahans,Korng Ea et al.
Vincent Guigonis et al.
Agnès Linglart,Caroline Silve,Anya Rothenbuhler
Agnès Linglart
Molecular alterations of cAMP-mediated signaling affect primarily the signaling of the PTH/PTHrp receptor, and, with different severities the signaling of other hormones, including TSH. The identification of PTH and other hormonal resistanc...
John O Prior
John O Prior
Benefits and place of calcimimetics in the management of primary hyperparathyroidism [0.03%]
拟钙剂在原发性甲状旁腺功能亢进治疗中的地位和作用
Christian Meier
Christian Meier
Anthony P Weetman
Anthony P Weetman